Advertisement
ALGN or IDXX or SYK
Which Stock Would AI Choose? Align Technology (ALGN) vs. IDEXX Laboratories (IDXX) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- ALGN reported record Q2 2026 revenue of $1.06 billion driven by clear aligner shipments, with management maintaining modest growth guidance amid strategic reviews.
- IDXX is scheduled to release Q2 2026 results on August 4, positioning the stock ahead of potential catalysts in veterinary diagnostics.
- SYK delivered Q2 sales of $6.59 billion and net income of $1.28 billion but saw its share price decline over 6% following the report due to sales expectations.
- The three companies operate in distinct healthcare niches—orthodontics for ALGN, animal health diagnostics for IDXX, and medical devices/surgery for SYK—creating varied exposure to consumer and institutional demand.
- Recent market activity shows mixed price responses to earnings, with valuation sensitivity and sector-specific momentum influencing relative performance.
Introduction
This comparison examines ALGN, IDXX, and SYK, three healthcare-focused equities with differentiated business models. Align Technology specializes in clear aligners and digital dentistry, IDEXX Laboratories leads in veterinary diagnostics and software, and Stryker Corporation provides a broad portfolio of medical devices and equipment. Investors and traders seeking to understand relative performance across orthodontics, animal health, and surgical technologies may find this analysis relevant for assessing sector positioning and recent momentum in the current market environment.
ALGN Overview and Recent Performance
Align Technology, Inc. develops and markets the Invisalign system of clear aligners along with intraoral scanners and related services. In recent weeks, the company announced Q2 2026 results showing record revenue of $1.06 billion, supported by strong clear aligner volumes and international growth. Systems and services revenue faced pressure from shifts toward lower-priced scanners. Management reiterated guidance for continued aligner growth and margin expansion while outlining strategic initiatives, including new director appointments and an operational review. Stock price action reflected volatility around the earnings release, consistent with sensitivity to quarterly execution and macroeconomic factors affecting elective procedures.
IDXX Overview and Recent Performance
IDEXX Laboratories, Inc. provides diagnostic products, software, and services primarily for companion animal veterinary practices. The company is positioned ahead of its Q2 2026 earnings release scheduled for August 4. Recent market activity indicates the shares have traded in a range amid broader healthcare sector movements and anticipation of results. Year-to-date performance has shown declines relative to some benchmarks, with analysts projecting year-over-year EPS growth. Sentiment remains tied to veterinary practice spending trends and the company’s recurring revenue streams from consumables and subscriptions.
SYK Overview and Recent Performance
Stryker Corporation manufactures and sells medical devices and equipment across MedSurg, Neurotechnology, and Orthopaedics segments. In recent market activity, the company reported Q2 2026 sales of $6.59 billion and net income of $1.28 billion. The stock declined approximately 6.4% following the release, attributed in part to sales expectations. Management maintained adjusted EPS guidance for the year while navigating supply chain and operational factors, including recovery from a prior cyber incident. Broader performance reflects steady demand for elective and acute care procedures alongside valuation considerations in the medical technology space.
Trending AI Robots
Tickeron’s Trending AI Robots page highlights a curated selection of AI trading bots from hundreds available that trade thousands of different tickers. Only the best and most suitable for current market conditions earn placement in this section. The bots feature a wide range of trading styles, strategies, timeframes, performance metrics, and ticker sets, allowing users to review statistics and backtested results across diverse approaches. This resource provides traders with data-driven options tailored to evolving conditions. Explore the full selection on the Trending AI Robots page.
Head-to-Head Comparison
The three stocks differ markedly in business models and growth drivers. ALGN depends on consumer-driven orthodontic demand and digital platform adoption, exposing it to discretionary spending and regulatory environments. IDXX benefits from recurring diagnostic testing volumes in veterinary care, offering relative stability but sensitivity to practice economics. SYK maintains diversified exposure across surgical and hospital products, supporting resilience through institutional purchasing cycles. Recent momentum varied, with ALGN posting record revenue, SYK facing post-earnings pressure, and IDXX awaiting results. Risk factors include macroeconomic headwinds for elective procedures at ALGN, competition in diagnostics for IDXX, and integration or supply issues for SYK. Valuation sensitivity differs by growth profile and sector positioning, with market sentiment reflecting earnings execution and forward guidance.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings delivery, and relative positioning in recent market activity, Tickeron’s AI would currently assign a higher probabilistic preference to SYK for its scale and maintained guidance despite short-term price reaction, while noting ALGN’s revenue achievement and IDXX’s upcoming catalyst as supportive elements. Outcomes remain subject to broader market conditions and individual company execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALGN’s FA Score shows that 1 FA rating(s) are green whileIDXX’s FA Score has 1 green FA rating(s), and SYK’s FA Score reflects 1 green FA rating(s).
- ALGN’s FA Score: 1 green, 4 red.
- IDXX’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALGN’s TA Score shows that 4 TA indicator(s) are bullish while IDXX’s TA Score has 7 bullish TA indicator(s), and SYK’s TA Score reflects 5 bullish TA indicator(s).
- ALGN’s TA Score: 4 bullish, 5 bearish.
- IDXX’s TA Score: 7 bullish, 2 bearish.
- SYK’s TA Score: 5 bullish, 3 bearish.
Price Growth
ALGN (@Pharmaceuticals: Other) experienced а +2.66% price change this week, while IDXX (@Medical Specialties) price change was +4.94% , and SYK (@Medical/Nursing Services) price fluctuated +4.09% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.28%. For the same industry, the average monthly price growth was +5.47%, and the average quarterly price growth was +2.65%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +6.88%. For the same industry, the average monthly price growth was +8.02%, and the average quarterly price growth was +20.04%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +5.89%. For the same industry, the average monthly price growth was -1.59%, and the average quarterly price growth was -8.72%.
Reported Earning Dates
ALGN is expected to report earnings on Oct 28, 2026.
IDXX is expected to report earnings on Nov 03, 2026.
SYK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+4.28% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (+6.88% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (+5.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| ALGN | IDXX | SYK | |
| Capitalization | 12.3B | 46.2B | 130B |
| EBITDA | 877M | 1.56B | 6.44B |
| Gain YTD | 11.214 | -13.282 | -3.020 |
| P/E Ratio | 30.17 | 41.23 | 35.13 |
| Revenue | 4.1B | 4.45B | 25.3B |
| Total Cash | 1.06B | 201M | N/A |
| Total Debt | 116M | 1.11B | 14.7B |
ALGN | IDXX | SYK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | 80 Overvalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 60 | |
SMR RATING 1..100 | 69 | 16 | 56 | |
PRICE GROWTH RATING 1..100 | 52 | 54 | 50 | |
P/E GROWTH RATING 1..100 | 26 | 79 | 83 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYK's Valuation (9) in the Medical Specialties industry is somewhat better than the same rating for ALGN (62) and is significantly better than the same rating for IDXX (80). This means that SYK's stock grew somewhat faster than ALGN’s and significantly faster than IDXX’s over the last 12 months.
SYK's Profit vs Risk Rating (60) in the Medical Specialties industry is somewhat better than the same rating for ALGN (100) and is somewhat better than the same rating for IDXX (100). This means that SYK's stock grew somewhat faster than ALGN’s and somewhat faster than IDXX’s over the last 12 months.
IDXX's SMR Rating (16) in the Medical Specialties industry is somewhat better than the same rating for SYK (56) and is somewhat better than the same rating for ALGN (69). This means that IDXX's stock grew somewhat faster than SYK’s and somewhat faster than ALGN’s over the last 12 months.
SYK's Price Growth Rating (50) in the Medical Specialties industry is in the same range as ALGN (52) and is in the same range as IDXX (54). This means that SYK's stock grew similarly to ALGN’s and similarly to IDXX’s over the last 12 months.
ALGN's P/E Growth Rating (26) in the Medical Specialties industry is somewhat better than the same rating for IDXX (79) and is somewhat better than the same rating for SYK (83). This means that ALGN's stock grew somewhat faster than IDXX’s and somewhat faster than SYK’s over the last 12 months.
| ALGN | IDXX | SYK | |
|---|---|---|---|
| RSI ODDS (%) | N/A | N/A | N/A |
| Stochastic ODDS (%) | 3 days ago 81% | 3 days ago 59% | 3 days ago 53% |
| Momentum ODDS (%) | 3 days ago 70% | 3 days ago 55% | 3 days ago 57% |
| MACD ODDS (%) | 3 days ago 80% | 3 days ago 65% | 3 days ago 62% |
| TrendWeek ODDS (%) | 3 days ago 73% | 3 days ago 59% | 3 days ago 55% |
| TrendMonth ODDS (%) | 3 days ago 76% | 3 days ago 53% | 3 days ago 48% |
| Advances ODDS (%) | 5 days ago 70% | 6 days ago 59% | 3 days ago 56% |
| Declines ODDS (%) | 10 days ago 74% | 18 days ago 70% | 10 days ago 52% |
| BollingerBands ODDS (%) | 3 days ago 79% | 3 days ago 77% | 3 days ago 55% |
| Aroon ODDS (%) | 3 days ago 78% | 3 days ago 54% | 3 days ago 51% |
Advertisement
IDXX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IDXX has been loosely correlated with ALGN. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if IDXX jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To IDXX | 1D Price Change % | ||
|---|---|---|---|---|
| IDXX | 100% | -0.56% | ||
| ALGN - IDXX | 50% Loosely correlated | +2.71% | ||
| SYK - IDXX | 48% Loosely correlated | +0.47% | ||
| BLCO - IDXX | 45% Loosely correlated | +2.63% | ||
| SNN - IDXX | 44% Loosely correlated | +1.41% | ||
| RVTY - IDXX | 41% Loosely correlated | +0.37% | ||
More | ||||
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.